![]() |
市場調查報告書
商品編碼
1727104
醫療經濟·結果調查(HEOR)服務市場:各類服務,各服務供應商,各終端用戶,各地區,機會,預測,2018年~2032年Health Economics and Outcomes Research (HEOR) Services Market Assessment, By Services, By Service Provider, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
全球衛生經濟學與成果研究 (HEOR) 服務市場規模預計將從 2024 年的 14.6 億美元增長至 2032 年的 36.6 億美元,在 2025-2032 年預測期內的複合年增長率為 12.15%。市場成長的推動因素包括:對成果數據和真實世界證據(用於報銷)的需求不斷增長;主要研究機構和政府機構對研發活動的投入不斷增加;以及製藥和生物技術公司對 HEOR 服務的使用率不斷提高。此外,臨床試驗數量的增加也推動了市場的成長。此外,全球各地臨床試驗數量的增加也推動了市場需求的成長。截至 2025 年 5 月 2 日,ClinicalTrials.gov 網站已註冊了 536,389 項研究。 ClinicalTrials.gov 是由美國國立衛生研究院 (NIH) 下屬的國家醫學圖書館 (NLM) 營運的公共註冊和結果資料庫。
在確保病患群體獲得優質醫療服務的同時,控制醫療成本的壓力日益增大,以及循證決策在報銷和臨床框架中的重要性日益提升,這些因素也在推動市場成長。此外,對基於價值的醫療服務、報銷流程的優化以及藥品價格透明度的日益關注也在推動市場擴張。
本報告提供全球醫療經濟·結果調查(HEOR)服務市場相關調查,提供市場概要,以及各類服務,各服務供應商,各終端用戶,各地區趨勢,及加入此市場的主要企業簡介等資訊。
Global health economics and outcomes research (HEOR) services market is projected to witness a CAGR of 12.15% during the forecast period 2025-2032, growing from USD 1.46 billion in 2024 to USD 3.66 billion in 2032. The market's growth is bolstered by the increasing requirements for outcome data and real-world evidence for reimbursement, increasing investments in research and development activities by leading research and government organizations, and rising utilization of HEOR services by pharmaceutical and biotech companies. Additionally, the increasing number of clinical trials is also driving the market's growth. Moreover, the rising number of clinical trials in different regions across the globe is also bolstering the market's demand. As of 2nd May 2025, 536,389 studies are registered at ClinicalTrials.gov, the publicly available registry and results database, which is run by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).
The market's growth is also bolstered by the increasing pressure to control healthcare costs while ensuring that the patient population is provided with high-quality care, along with the rising importance of evidence-based decision making in reimbursement and clinical frameworks. Furthermore, the growing focus on value-based care, optimization of reimbursement processes, and transparency in drug pricing are also propelling the market's expansion.
Technological Advancements Drive Market Demand
The market's growth is supported by the increasing focus on novel launches to provide high-quality services to the healthcare and biopharmaceutical industries. For instance, in November 2023, Stratevi LLC launched StrateFlow, a custom-built software to aid HEOR, medical, and access teams in enabling stakeholder alignment and project management while juggling priorities. The platform's three core modules include Project Planner, Evidence Hub, and HTA Optimizer, which streamline project management, centralize evidence and value communication, and facilitate efficient planning and tracking of HTA submissions across the globe. As pharmaceutical companies increasingly rely on digital solutions to manage increasing data complexities and regulatory demands, platforms such as StrateFlow are expanding the capabilities and reach of HEOR services. This innovation not only improves internal processes but also strengthens the ability of HEOR teams to demonstrate product value, ultimately fueling the growth of the market.
Strategic Alliances Support Market Expansion
Strategic alliances, including partnerships, mergers, and acquisitions, allow companies to combine their expertise and resources, aiding them in expanding their customer base and improving their service portfolios. Alliances also support innovation by ensuring the integration of resources and skills, streamlining complex processes such as regulatory compliance and drug development for pharmaceutical and biotech companies.
In April 2024, PharmAlliance, Inc. acquired Complete Health Economics Outcomes Research Solutions (CHEORS), allowing the former to expand its market presence and ensure the launch and commercialization of new products and services. The latter holds expertise in health technology assessment (HTA), economic modeling, and evidence synthesis. Such partnerships accelerate the adoption of HEOR services by providing clients with data-driven insights, facilitating rapid and efficient decision-making.
Consultancy Accounts for Significant Share of the Market
The segment's dominance can be attributed to the role of consultancies in providing strategic guidance and expertise to healthcare, biotech, and pharmaceutical companies in navigating complex reimbursement policies and regulatory environments. These organizations offer customized solutions in a wide range of domains, including economic modeling, pricing, market access, and real-world evidence, which are essential for demonstrating product value to healthcare professionals, policy regulators, and payers.
Furthermore, the rising collaborations between consultancies and market vendors are also supporting the segment's growth, providing lucrative growth opportunities for the market. For instance, in August 2024, ADVI Health, LLC acquired Partnership for Health Analytic Research, LLC, a global HEOR consultancy known for providing data-driven and high-impact insights to biopharmaceutical clients and sponsors. Such acquisitions ensure expertise integration and consolidation in the consultancy sector, allowing them to meet the rising requirements for HEOR services and expand their service portfolios, while fueling innovation, thus providing lucrative growth opportunities for the market.
North America Holds Major Market Share
The high adoption rate of evidence-based reimbursement models, a strong pharmaceutical industry, and easy availability and acceptance of advanced technologies support the market's growth in North America. The market is expected to witness significant growth in the United States due to the country's increasing emphasis on outcome-based contracts, strong cost-containment policies, and high drug approvals. Additionally, the strong presence of CROs (contract research organizations and biopharmaceutical companies) and biopharmaceutical companies is further accelerating the demand for HEOR services in both commercial and clinical applications. Additionally, different government policies to bolster the affordability of different medications are also providing lucrative growth opportunities for the market.
For instance, the Inflation Reduction Act (IRA), signed into law in August 2022, in the United States, introduced new drug pricing reforms and emphasized cost-effectiveness thresholds in Medicare price negotiations, resulting in increased reliance on HEOR services to support the introduction of evidence-based pricing strategies.
Impact of U.S. Tariffs on Global Health Economics and Outcomes Research (HEOR) Services Market
The tariffs are increasing medical supply and device costs, resulting in the limited availability of resources to HEOR services. The increased financial strains could also hinder the ability of research organizations and healthcare systems to invest in comprehensive outcome research, impacting long-term healthcare planning.
Market players may need to develop more adaptable and resilient research methodologies, incorporating diverse analytical techniques and data sources to navigate the evolving healthcare industry. By embracing real-world evidence and digital health technologies, the companies can bolster the effectiveness of HEOR services.
Key Players Landscape and Outlook
The key players of the market are focusing on launching novel technological solutions to expand their customer base by providing cutting-edge solutions to leading pharmaceutical, biotech, and research organizations. For instance, in June 2024, IQVIA Inc. launched One Home for Sites, a new platform that functions as a single dashboard and a single sign-on for key tasks and systems a clinical research site requires to perform across all the clinical trials they are conducting. One Home integrates a wide range of digital tools, data, and services into a unified ecosystem, supporting both decentralized and hybrid clinical trial models. The platform aims to streamline trial operations, enhance patient engagement, and improve data quality by offering real-time insights and seamless stakeholder coordination.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.